One Shot to Rule Them All: Europe's Bet on a Flu-COVID Combo Vaccine
Europe just greenlit the world's first combined flu-COVID vaccine, and it's not just a convenience play. Moderna's mCOMBRIAX could reshape seasonal vaccination, plug a dangerous coverage gap in older adults, and throw the company a financial lifeline it desperately needs.
Every fall, millions of Europeans over 50 face the same annoying ritual. One appointment for the flu shot. Another for the COVID booster. Different pharmacies, different schedules, different sore arms. It's like being forced to make two separate trips to the grocery store for bread and milk.
The European Commission just said: enough. On April 21, 2026, it granted marketing authorization to mCOMBRIAX, Moderna's combined flu and COVID-19 mRNA vaccine for adults 50 and older. It's the world's first approved combination vaccine targeting both influenza and COVID-19, and it could reshape how Europe handles respiratory season.
One shot. Two diseases. Twenty-seven EU countries (plus Iceland, Liechtenstein, and Norway) now have access.
Why This Matters More Than You Think
The approval might sound incremental. It's not. This is the first real proof that combination respiratory vaccines actually work well enough to get a regulator's stamp. And the data backing it up isn't just "good enough"; it's surprisingly strong.
Moderna's pivotal Phase 3 trial enrolled roughly 8,000 adults split into two age groups. Adults 65 and older received mCOMBRIAX or the combo of a high-dose flu shot (Fluzone High-Dose) plus Moderna's standalone COVID vaccine (Spikevax). Adults 50 to 64 got mCOMBRIAX or a standard flu vaccine (Fluarix) plus Spikevax.
The results cleared every primary endpoint. mCOMBRIAX didn't just match the separate vaccines; it beat them. Immune responses were statistically higher against three influenza strains (A/H1N1, A/H3N2, and B/Victoria) and against SARS-CoV-2 in the older age group. In the 50-to-64 group, it outperformed across all four flu strains and COVID.
Think of it like a combo meal that somehow tastes better than ordering each item separately. That almost never happens.
The Safety Question Everyone Asks
Whenever you combine two vaccines, the natural worry is side effects. More ingredients, more chances for your immune system to throw a tantrum, right?
The trial data here is reassuring. Local reaction rates were approximately , compared to roughly 70–76% in the groups getting separate shots. So yes, slightly more reactions, but the vast majority were mild or moderate, grade 1 or 2 on the severity scale. Those numbers held through the follow-up period.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
75–79% for mCOMBRIAX participants
The EMA's committee (CHMP) reviewed all of this before issuing a positive opinion in February 2026. The European Commission followed with full authorization two months later.
Europe's Embarrassing Vaccination Gap
Here's where the story gets interesting from a public health angle. Europe has a massive vaccination problem in older adults, and a combo vaccine might be the best tool to fix it.
The numbers are stark. Among Europeans 65 and older, flu vaccination rates hover around 45–48%, well below the 75% coverage target set by the WHO and the EU Council. Only two countries hit that benchmark in the 2023–24 season. COVID booster coverage is even worse: a median of just 14% among people 60 and older, with some countries barely registering above zero.
Meanwhile, this same age group accounts for roughly a third of all flu-related hospitalizations and a staggering 90% of flu-associated deaths in Europe. The continent spends an estimated €11.5 billion annually on influenza hospitalizations. That's a lot of preventable suffering and a lot of wasted money.
So why aren't more older Europeans getting vaccinated? Convenience is a huge factor. Scheduling two separate appointments, navigating different vaccine availability windows, dealing with pharmacy logistics: it all creates friction. A discrete-choice study across France, Italy, and other EU countries found that most older adults preferred a single combination shot over two separate vaccines. Modeled scenarios showed that offering a flu-COVID combo could meaningfully lift coverage for both diseases.
In other words, the biggest barrier to vaccination isn't hesitancy. It's hassle. And mCOMBRIAX eliminates half the hassle in one stroke.
Moderna's Billion-Dollar Lifeline
For Moderna, this approval couldn't come at a better time. The company is navigating what you might call its post-pandemic hangover.
Q2 2025 revenue came in at just $142 million, down 41% from the same quarter a year earlier. COVID vaccine demand keeps shrinking. Moderna's U.S. market share in COVID vaccines was 48% in the fall 2023 season. Its RSV vaccine, mRESVIA, generated negligible sales. The company cut its full-year 2025 revenue guidance to $1.5–$2.2 billion and announced a $1.5 billion cost-cutting program, including a 10% workforce reduction.
Moderna needs new revenue streams, and it needs them fast. CEO Stéphane Bancel has been vocal about building a "seasonal respiratory vaccine franchise" that serves as a durable cash engine to fund the company's ambitions in oncology and rare disease.
The respiratory vaccine market is enormous. Moderna sizes the opportunity at roughly $30 billion annually across COVID, RSV, and influenza. The company's internal target: $8–15 billion in respiratory franchise sales by 2027. That's ambitious, bordering on audacious, given a 2025 revenue base around $2 billion. But mCOMBRIAX is the first concrete step toward making that vision real.
The 2026 guidance calls for roughly 10% revenue growth, with no contribution assumed from flu or combo vaccines. That means any commercial traction from mCOMBRIAX in Europe represents pure upside. And Moderna is also planning to shift toward a 50/50 revenue split between U.S. and international markets by 2026, partly through new local manufacturing in the U.K. and Australia.
The Race Moderna Is Winning (For Now)
Moderna isn't the only company chasing combination respiratory vaccines, but it has a meaningful lead where it counts most.
Pfizer and BioNTech are also developing an mRNA flu-COVID combo, but Pfizer hit a speed bump: its vaccine showed suboptimal immune responses against influenza B strains in a trial cohort, raising questions about the breadth and pace of further approvals.
Moderna's mCOMBRIAX, by contrast, demonstrated superiority against the influenza B/Victoria strain in both age cohorts. That's a meaningful clinical differentiator. However, Moderna's U.S. path has encountered its own obstacles: the company withdrew its U.S. mCOMBRIAX application in May 2025 and is awaiting further FDA guidance on when it can refile, making a U.S. launch unlikely before 2027 at the earliest.
Behind the two mRNA leaders, the field thins out quickly. Novavax and Sanofi have a $1.2 billion partnership to develop protein-based COVID-flu combinations using Novavax's Matrix-M adjuvant. It's an appealing option for people who prefer non-mRNA vaccines, but approvals aren't expected until 2026–2029. GSK and CureVac are working on mRNA respiratory combos, and J&J has programs in the space, but both are considered "second wave" entrants unlikely to reach market before the late 2020s.
For now, the combination respiratory vaccine market is essentially a two-horse race between Moderna and Pfizer/BioNTech.
What Comes After the Combo
If mCOMBRIAX is chapter one, Moderna is already writing the sequel. The company has a triple combination vaccine (mRNA-1230) targeting flu, COVID, and RSV simultaneously in Phase 1/2 trials. There's also a flu-plus-RSV combo (mRNA-1045) and an RSV-plus-human-metapneumovirus candidate (mRNA-1365) in early development.
The endgame is clear: a single annual shot that protects against every major respiratory virus. Imagine walking into a pharmacy each October, rolling up your sleeve once, and being covered for flu, COVID, RSV, and potentially more. That's the world Moderna is trying to build.
Whether Moderna can actually execute on all of this while burning cash and managing a shrinking COVID franchise is the central tension of the company's story. The standalone flu vaccine (mRNA-1010) is under regulatory review in the U.S., EU, Canada, and Australia. The norovirus vaccine is in Phase 3. Oncology programs are getting more investment as R&D dollars shift away from earlier-stage respiratory work.
The Bottom Line
mCOMBRIAX's European approval is more than a regulatory checkbox. It validates the idea that combination mRNA vaccines can match or beat existing vaccines against multiple diseases at once. It gives Moderna a new product in a market worth billions annually. And it offers European health systems a practical tool to close a dangerous vaccination gap in their most vulnerable populations.
The seasonal respiratory vaccine market has operated the same way for decades: one disease, one shot, one appointment at a time. That era is ending. The only question now is how fast the world catches up to what Europe just approved.
Funding & Financings5 min read
$715 Million in 48 Hours: The Two Bets Reshaping Biotech
Two of 2026's largest biotech venture rounds landed on back-to-back days: $400 million for AI drug designer Chai Discovery and $315 million for radiopharmaceutical developer AdvanCell. The $715 million blitz reveals exactly where smart money thinks the future of drug development is headed.
